Effect of TA-65MD on Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TA-65 MD® is pure, natural, plant-based compound that can help maintain or rebuild telomeres. A telomere is a region of repetitive DNA at the end of a chromosome, which protects the end of the chromosome from deterioration. They shorten during cell division and eventually signal an irreversible state of growth arrest known as cellular senescence. The length of a person's telomeres is an indicator of his or her overall health status; short telomeres have been associated with cellular aging and dysfunction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TA-65 and Aging Associated Microvascular Dysfunction

NCT05598359

Telomere Shortening Aging Vascular Diseases

NOT_YET_RECRUITING NA

TA-65 Pharmacokinetic Study

NCT02731807

Healthy

COMPLETED PHASE1

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

NCT01753674

Metabolic Syndrome Insulin Resistance

TERMINATED PHASE1

Effects of TA-65, a Telomerase Activator on Metabolic Syndrome

NCT02531334

Metabolic Syndrome X

COMPLETED NA

Anti-age Dietary Supplements in Healthy Older Adults: the proBNPage Reduction Trial

NCT05500742

Aging

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this clinical study is to evaluate the effects of TA-65 MD® on telomere length and on immunosenescence in subjects who have had 9 months of twice daily TA-65 MD® administration, compared to placebo. TA Sciences has developed different doses of TA-65® . The study intends to determine effect of four different doses of TA-65 MD® in terms of biomarkers, telomere length and overall health and sleep status.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Intervention Type DIETARY_SUPPLEMENT

TA-65, a purified small molecule extracted from Astragalus root

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TA-65MD

TA-65, a purified small molecule extracted from Astragalus root

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo, an inactive formulation

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy adult males or females, based on medical history and current status.
2. Ages 45-75 years of age (inclusive at the time of Screening).
3. Voluntary consent and methods completion of a signed ICF (informed consent form).
4. BMI that is 18 to 40 kg/m2 (inclusive at the time of Screening).
5. Subjects who are able to understand and comply with protocol requirements, instructions, and protocol-stated restrictions.

\-

Exclusion Criteria

1. History or presence of clinically significant cardiovascular, pulmonary, respiratory, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
2. History of HIV, Hepatitis B, or Hepatitis C.
3. Females who are pregnant, planning to become pregnant during the study, or breastfeeding.
4. Recent or current medical condition that might significantly affect a pharmacodynamic response or compromise the safety of the subject or impact the validity of the study results in the opinion of the Investigator. (e.g., conditions that require taking diuretic medications and/or cardiac stimulants.)
5. Intake of the investigational product within 30 days prior to screening visit.
6. History of an allergic reaction to the study products or ingredient(s) or to comparable products in the opinion of the Investigator.
7. History of drug or alcohol addiction or abuse within 1 year prior to Day -1 product administration through end of study (EOS).
8. Donation of blood within 30 days or plasma within 7 days, prior to Day -1 product administration through EOS.
9. Intolerance to venipuncture or an inability to swallow capsules.

\-

Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes